News and insights into the #2 pharma/medtech market - China

Greg B. Scott founded ChinaBio® in 2007 to help western life science companies achieve success in China. ChinaBio® is a consulting and advisory firm based in Shanghai that has helped over 100 U.S., European and APAC companies seeking partnerships, acquisitions, novel ... more

ALL CONTRIBUTIONS

Week In Review: VistaGen Out-Licenses China/Asia Rights For Novel Anxiety Drug To EverInsight In $177 Million Deal
VistaGen of South San Francisco out-licensed China/Southeast Asia rights for a novel anxiety treatment to EverInsight Therapeutics, a China in-licensing company, in a $177 million agreement.
Read
Week In Review: Six China Biopharma Deals Raise A Total Of $255 Million
Immvira Group, a Shenzhen biotech developing oncolytic virus therapies, completed a $58 million Series B financing. Miaoshou Doctor, an online-offline healthcare company headquartered in Beijing, closed an $85 million Series D1 round.
Read
Week In Review: Suzhou Innovent Announces $2 Billion Immunotherapy Collaboration With Roche
Suzhou Innovent Bio formed a far-reaching R&D collaboration with Roche that has a potential value of over $2 billion. Roche will have an option to license each product for ex-China development and commercialization.
Read
Week In Review: China Life Science Companies Raise Nearly $1 Billion Led By Legend's $424 Million US IPO
In a successful debut offering, Nanjing Legend Biotech priced its US IPO above the expected range at $23 per ADS, raising $424 million. The company's ADS's climbed 60% higher to $36.60, giving Legend a market capitalization of nearly $5 billion.
Read
Week In Review: Shenzhen's MGI Tech Raises $1 Billion To Develop Gene Sequencing Machines
MGI Tech of Shenzhen, a company making gene-sequencing machines and related equipment, completed a $1 billion Series B round led by IDG Capital and CPE. Suzhou Kintor Pharma completed a $240 million IPO on the Hong Kong Exchange.
Read
Week In Review: CanSino Publishes Positive Data From Trial Of COVID-19 Vaccine
Tianjin CanSinoBIO published positive results from a China Phase I trial of its COVID-19 vaccine in the prestigious British journal, The Lancet. In the study, the Ad5 vectored COVID-19 vaccine was immunogenic at 28 days post-vaccination.
Read

STOCKS I FOLLOW

AXN Aoxing Pharmaceutical Company, Inc.
CRPNF China Pioneer Pharma Holdings Ltd.
CYIG CHINA YCT INTL GROUP
HCM Hutchison Chi-Med
ICLR Icon PLC
MCRPF MICROPORT SCIENTIFIC
MDCO The Medicines Company
MR Mindray Medical International Limited
NBY NovaBay Pharmaceuticals, Inc.
SCLN SciClone Pharmaceuticals, Inc.
WX WuXi PharmaTech Inc.
Load More

TWEETS

PERSONAL BLOG

Latest Posts

Work Experience

Education

Publications